Literature DB >> 925881

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

L B Sheiner, B Rosenberg, V V Marathe.   

Abstract

Mesh：

Substances：

Year:  1977        PMID： 925881     DOI： 10.1007/bf01061728

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  27 in total

1.  Determinants of the renal clearance of digoxin.

Authors:  H Halkin; L B Sheiner; C C Peck; K L Melmon
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

2.  STUDIES WITH TRITIATED DIGOXIN IN RENAL FAILURE.

Authors:  J E DOHERTY; W H PERKINS; M C WILSON
Journal:  Am J Med       Date:  1964-10       Impact factor: 4.965

3.  STUDIES FOLLOWING INTRAMUSCULAR TRITIATED DIGOXIN IN HUMAN SUBJECTS.

Authors:  J E DOHERTY; W H PERKINS
Journal:  Am J Cardiol       Date:  1965-02       Impact factor: 2.778

4.  Differences in serum digoxin concentrations between outpatients and inpatients: an effect of compliance?

Authors:  L B Sheiner; B Rosenberg; V V Marathe; C Peck
Journal:  Clin Pharmacol Ther       Date:  1974-03       Impact factor: 6.875

5.  Renal tubular secretion of digoxin.

Authors:  E Steiness
Journal:  Circulation       Date:  1974-07       Impact factor: 29.690

6.  Variability of standard curves in radioimmunoassay of plasma digoxin.

Authors:  G H Burnett; R L Conklin; G W Wasson; A A MacKinney
Journal:  Clin Chem       Date:  1973-07       Impact factor: 8.327

7.  Absorption of orally given digoxin preparations.

Authors:  D H Huffman; D L Azarnoff
Journal:  JAMA       Date:  1972-11-20       Impact factor: 56.272

8.  Computer-assisted digoxin therapy.

Authors:  C C Peck; L B Sheiner; C M Martin; D T Combs; K L Melmon
Journal:  N Engl J Med       Date:  1973-08-30       Impact factor: 91.245

9.  Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay.

Authors:  T W Smith; V P Butler; E Haber
Journal:  N Engl J Med       Date:  1969-11-27       Impact factor: 91.245

10.  Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications.

Authors:  D J Sumner; A J Russell
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335
View more
  210 in total

1.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

Authors:  B Vadher; D L Patterson; M Leaning
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  A population approach to enzyme characterization and identification: application to phenacetin O-deethylation.

Authors:  D J Belle; B J Ring; S R Allerheiligen; M A Heathman; L M O'Brien; V Sinha; L K Roskos; S A Wrighton
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

3.  Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis.

Authors:  S C Olson; H Bockbrader; R A Boyd; J Cook; J R Koup; R L Lalonde; P H Siedlik; J R Powell
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

4.  Nonlinearity detection: advantages of nonlinear mixed-effects modeling.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  AAPS PharmSci       Date:  2000

5.  Software for population pharmacokinetics and pharmacodynamics.

Authors:  L Aarons
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

6.  Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.

Authors:  Ene I Ette; Leonard C Onyiah
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jul-Sep       Impact factor: 2.441

7.  Population pharmacokinetics of daptomycin.

Authors:  Barry Dvorchik; Robert D Arbeit; Julia Chung; Susan Liu; William Knebel; Helen Kastrissios
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.

Authors:  Yuyan Jin; Bruce G Pollock; Ellen Frank; Jeff Florian; Margaret Kirshner; Andrea Fagiolini; David J Kupfer; Marc R Gastonguay; Gail Kepple; Yan Feng; Robert R Bies
Journal:  J Clin Pharmacol       Date:  2009-02       Impact factor: 3.126

9.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.

Authors:  Yuan Ji; Daniel J Schaid; Zeruesenay Desta; Michiaki Kubo; Anthony J Batzler; Karen Snyder; Taisei Mushiroda; Naoyuki Kamatani; Evan Ogburn; Daniel Hall-Flavin; David Flockhart; Yusuke Nakamura; David A Mrazek; Richard M Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.